Subscribe to RSS
DOI: 10.1055/s-0038-1646897
A Second Plasma Inhibitor of Activated Protein C: α1-Antitrypsin
Publication History
Received 07 January 1989
Accepted after revision 05 May 1989
Publication Date:
30 June 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/198902/lookinside/thumbnails/10-1055-s-0038-1646897-1.jpg)
Summary
Inactivation of activated protein C (APC) in normal human plasma was studied in the absence and presence of heparin. In the absence of heparin APC inactivation followed pseudo-first order kinetics. In the presence of heparin the neutralization of APC was found to be biphasic. Up to 500 nM APC could be readily inactivated in normal plasma, indicating that the concentration of the APC inhibitor must be higher than previously assumed. Plasma deficient in the protein C inhibitor (PCI-I, as described by Suzuki and coworkers) and deficient in p2-glycoprotein I still possessed APC neutralizing capacity, presumably through the formation of complexes of APC with another plasma protein as was demonstrated by immunoblotting with anti-protein C antibodies. Together these data made us to conclude that a second inhibitor of APC (PCI-II) must be present in normal human plasma. This second inhibitor should be heparin independent, have a relatively high plasma concentration and form complexes with APC.
Subsequently, we purified this PCI-II by isolating APC-PCI-II complexes from plasma deficient of vitamin K dependent proteins, PCI-I and β2-glycoprotein-I, to which purified human APC had been added. Purified PCI-II has a molecular weight of 50,000 daltons and aminoacid analysis revealed that PCI-II is identical with α1-antitrypsin (α1-AT). The second order rate constant for the reaction between purified α1-AT and APC was found to be 269 M−1 min−1 in the absence of calcium and 602 M−1 min−1 in the presence of calcium.
Finally, the analysis of the kinetics of APC inactivation in the plasma of a patient congenitally deficient in α1-AT (3% α1-AT antigen) revealed that there probably is a third inhibitor of APC in plasma, different from PCI-I and from α1-AT.
-
References
- 1 Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235: 1348-1352
- 2 Marlar RA, Griffin JH. Deficiency of protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest 1980; 66: 1186-1189
- 3 Gardiner JE, Griffin JH. Studies on human protein C inhibitor in normal and factor V/VIII deficient plasmas. Thromb Res 1984; 36 (03) 197-203
- 4 Canfield WM, Kisiel W. Evidence of normal functional levels of activated protein C inhibitor in combined factor V/VIII deficiency disease. J Clin Invest 1982; 70: 1260-1272
- 5 Schousboe I. β2-Grlycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985; 66 (05) 1086-1091
- 6 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor. Purification from human plasma and characterization. J Biol Chem 1983; 258 (01) 163-168
- 7 Suzuki K, Nishioka J, Kusumoto H, Hashimoto S. Mechanism of inhibition of activated protein C by protein C inhibitor. J Biochem 1984; 95: 187-195
- 8 Suzuki K. Biochemistry and physiology of protein C inhibitor. In: Protein C - Biochemical and Medical Aspects. Witt I. (ed) Walter de Gruyter Co; Berlin: 1985: 43-58
- 9 Heeb MJ, Espana F, Geiger M, Collen D, Stump DC, Griffin JH. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor III. J Biol Chem 1987; 262: 15813-15816
- 10 Bertina RM, Broekmans AW. Functional assays of plasma protein C. In: Protein C - Biochemical and Medical Aspects. Witt I. (ed) Walter de Gruyter Co; Berlin: 1985: 81-92
- 11 Meer FJ M v d, Tilburg NH v, Linden IK v d, Briet E, Bertina RM. A second inhibitor of activated protein C (APC). Thromb Haemostas 1987; 58: 277 (Abstr)
- 12 Heeb MJ, Griffin JH. Physiologic inhibition of human activated protein C by α2 antitrypsin. J Biol Chem 1988; 263: 11613-11616
- 13 Kramps JA, Brouwers JW, Maesen F, Dijkman JH. PiMhecrlcn, a piMallele resulting in very low α1-antitrypsin serum levels. Hum Genet 1981; 59: 104-107
- 14 Mertens K, Bertina RM. Pathways in the activation of human coagulation factor X. Biochem J 1980; 185: 647-658
- 15 Hinsbergh VW M v, Bertina RM, Wijngaarden Av, Tilburg NH v, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditional medium. Blood 1985; 65: 444-451
- 16 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-4412
- 17 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
- 18 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 1979; 76 (09) 4350-4354
- 19 Carrell RW, Jeppsson J-O, Laurell CB, Brennan SO, Owen MC, Vaughan L, Boswell DR. Structure and variation of human α1-antitrypsin. Nature 1982; 298: 329-334
- 20 Crockson RA, Payne CJ, Ratcliff AP, Soothill JF. Time sequence of acute phase reactive proteins following surgical trauma. Clin Chim Acta 1966; 14: 435-441